Health
New partnership aims to advance predictive tests for multiple myeloma in Ireland – News-Medical.Net
By combining genomic testing and next generation sequencing technology, a new partnership led by RCSI researchers aims to advance predictive tests for multiple myeloma, the second most common blood cancer in Ireland.
By combining genomic testing and next generation sequencing technology, a new partnership led by RCSI researchers aims to advance predictive tests for multiple myeloma (MM), the second most common blood cancer in Ireland.
The study will be carried out at Beaumont Hospital Dublin and run through the Blood Cancer Network Ireland with several other cancer hospitals in Ireland participating. It represents a collaboration between RCSI University of Medicine and Health Sciences and SkylineDx with fun…
-
Noosa News20 hours agoMoreton Bay oyster farm survives cyclone with help of wave wall innovation
-
Business22 hours ago$10,000 invested in ANZ shares 5 years ago is now worth…
-
Noosa News21 hours agoHelicopter pilots saving lives, providing food and fodder in flooded outback Queensland
-
General21 hours agoInternal Revenue Service starts cutting 20,000 workers